PSKW is the innovation driver in biopharma loyalty marketing. We develop, execute, and manage (1) co-pay assistance initiatives using an array of tangible and virtual distribution channels, and (2) digital relationship tools that enhance physician/patient dialogue and help drive compliance and adherence. Co-Pay Assistance Initiatives: PSKW created the co-pay assistance industry and ...

PDQ Communications, Inc.

PDQ Communications is a healthcare communications company, assisting pharmaceutical manufacturers and others to update healthcare professionals with product information in a timely manner. PDQ MAIL aids the pharmaceutical manufacturer by delivering their message to healthcare providers in all practice settings. Custom mailings feature FLASH branding and are targeted to the ...


DMD, a digital healthcare intelligence company, brings clarity to data overload in the fast-moving practice of marketing to healthcare professionals. DMD enables healthcare marketers to build ongoing relationships with HCPs via a uniquely sourced, micro-targeted, cross-channel database. Using robust email analytics and email asset optimization in a consultative partnership with ...

Subscribe today


Over 25,000 healthcare contacts at your fingertips

Get full online access and a copy of The PMD in print. 

Click for more information »

PMD ReFresh

High Climber

Alan Mateo, EVP, global sales, Veeva Systems


Ed Shankman, SVP, CCO, Natrel

More from ReFresh

Click here to sign up for the latest ReFresh, PMD's monthly newsletter update

Latest from MM&M

Tecfidera sales slow, Biogen to maintain "significant" sales force

The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.

Five things for pharma marketers to know: Friday, April 24

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Merck HCV med's efficacy matches competitors'

The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.